Back to Search
Start Over
Treatment-induced cell cycle kinetics dictate tumor response to chemotherapy
- Source :
- Oncotarget
- Publication Year :
- 2015
- Publisher :
- Impact Journals, LLC, 2015.
-
Abstract
- Chemotherapy fails to provide durable cure for the majority of cancer patients. To identify mechanisms associated with chemotherapy resistance, we identified genes differentially expressed before and after chemotherapeutic treatment of breast cancer patients. Treatment response resulted in either increased or decreased cell cycle gene expression. Tumors in which cell cycle gene expression was increased by chemotherapy were likely to be chemotherapy sensitive, whereas tumors in which cell cycle gene transcripts were decreased by chemotherapy were resistant to these agents. A gene expression signature that predicted these changes proved to be a robust and novel index that predicted the response of patients with breast, ovarian, and colon tumors to chemotherapy. Investigations in tumor cell lines supported these findings, and linked treatment induced cell cycle changes with p53 signaling and G1/G0 arrest. Hence, chemotherapy resistance, which can be predicted based on dynamics in cell cycle gene expression, is associated with TP53 integrity.
- Subjects :
- p53
Oncology
medicine.medical_specialty
medicine.medical_treatment
Antineoplastic Agents
Breast Neoplasms
Biology
chemotherapy
Breast cancer
Genes, Reporter
Cell Line, Tumor
Neoplasms
Internal medicine
Gene expression
medicine
Humans
Chemotherapy
Gene Expression Profiling
Cell Cycle
Cancer
Cell cycle
Flow Cytometry
medicine.disease
Immunohistochemistry
Cell Cycle Gene
Gene Expression Regulation, Neoplastic
Gene expression profiling
Drug Resistance, Neoplasm
Cell Cycle Kinetics
MCF-7 Cells
Female
Tumor Suppressor Protein p53
Research Paper
Signal Transduction
Subjects
Details
- ISSN :
- 19492553
- Volume :
- 6
- Database :
- OpenAIRE
- Journal :
- Oncotarget
- Accession number :
- edsair.doi.dedup.....4daf4b5549fd70a9c5a4cbcf7113253b
- Full Text :
- https://doi.org/10.18632/oncotarget.3140